, Australia
37 views

Healthcare prioritised in Australia’s 2021 budget: report

About $2.6b will be allocated towards vaccines.

Australia’s government has announced an investment of $76.39b (A$98.3b), or 17% of the country’s total expenditure, into the healthcare sector, revealing the sector to be a key spending priority in the country, according to a report from Fitch Solutions.

According to the budget statement, healthcare, defense, housing and payouts to the states will increase in FY21 compared to FY20. Of the healthcare spending, $2.6b (A$3.4b) will be allocated towards vaccines.

The government has also allocated $3.9b (A$5.1b) on the rollout alone to help provide support to states and territory in this regard, and has stated that the government hopes to have the bulk of the Australian population vaccinated by the end of the calendar year.

“Over recent months, the Australian government has come under criticism for delays faced in its Covid-19 vaccine roll-out. Multitude issues have emerged in this regard, including a supply shortage of the AstraZeneca vaccine,” the report stated.

In addition, the government will provide $678.5m (A$879m) over two years to support Medicare, including pathology for Covid-19 testing, telehealth services, commonwealth respiratory clinics; access to the pharmaceutical benefits scheme, supporting regional and remote Indigenous communities and mental wellbeing support through Beyond Blue.

Despite the economic woes brought on by the pandemic, causing Australia’s economy to contract by 2.5%, the report noted that government revenue collection surprised on the upside, staging a 3.8% increase in FY20 from FY19. The Treasury has attributed this to the success of the virus containment and various fiscal measures that provided a boost of household income.

However, sustainability of government-funded medicines will be increasingly questioned. Fitch noted that over the coming years, the government will be reassessing the public funds allocated to innovative health products. 

In particular, there will be new budget restrictions, more reference pricing, greater emphasis on cost-effectiveness studies and additional mechanisms to increase the uptake of cost-effective therapeutics such as generic drugs and biosimilars.

“The arrival of high-value pharmaceuticals to the treatment landscape will further incentivise the government to increase its cost-containment measures and encourage the switch to generic medicines where possible. This will place downward pressure on medicine sales growth on a value basis,” Fitch added.
 

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Get Health Care Asia Magazine in your inbox
It was recognised for its cutting-edge medical device packaging design, Dispenser Integrated System Kit (DISK).
There has been an expanding research base across India, China, and Japan.
It combines third-party assured data verification with blockchain technology.
Consultation is available for only $0.014 (INR1).
The number of hospitals operating on hip fracture that have access to a fracture liaison service has been steadily rising from 2013 to 2020.
GMT Manila’s award-winning initiative, in collaboration with Endec Inc. and Scilore LLC, is a rapidly deployable turnkey solution for RT-PCR Testing that made it more available across the Philippines. 
As The National Cardiovascular Referral Center in Indonesia, NCCHK has been acknowledged by Asia's Healthcare Industry.
Currently, North America dominates the market across the globe.
More medical devices are being bought for home use.
It has also introduced a new hotline service.
The firm was recognised for its multiple initiatives in braving the COVID-19 crisis.
It took home the Training Initiative of the Year trophy for its non-invasive therapy treatment for benign prostatic hyperplasia (BPH).
The country’s SII makes up about half of Covax supply.
It owns 39 hospitals and eight clinics across England, Wales, and Scotland.
The company plans to set up over 100 in-school clinics.